pharmaphorum

MARCH 27, 2022

AstraZeneca has bought a stake in digital health firm Huma Therapeutics in a deal that will see ownership of AZ’s AMAZE disease management platform transfer to the UK startup. The two companies say they plan to launch a series of Software as a Medical Device (SaMD) companion apps for various diseases, including asthma, chronic obstructive pulmonary disease (COPD) and heart failure, as well as technology for running decentralised clinical trials.

Hospitals 59

Hospitals 59

Pharma Mirror

MARCH 27, 2022

BARCELONA, Spain, More than 50 percent of patients with moderate-to-severe atopic dermatitis (AD) experienced at least 75 percent reduction in disease severity (EASI-75*) at 16 weeks when receiving lebrikizumab monotherapy in the ADvocate program, Almirall S.A. (BME: ALM) announced today at the American Academy of Dermatology (AAD) Annual Meeting. Lebrikizumab, an investigational IL-13 inhibitor, also led to clinically meaningful improvements in itch and other important patient-reported outcomes

52

52

Med Ed 101

MARCH 27, 2022

COPD is a challenging disease that ultimately leads to a progressive reduction in lung function. Our mainstays of therapy are the bronchodilators like long-acting anticholinergic and long-acting beta-agonists. Roflumilast (podcast) is a unique medication for COPD in that it is taken orally. I want to discuss roflumilast clinical pearls and where this medication might be […].

40

40

pharmaphorum

MARCH 27, 2022

Johnson & Johnson is in course for approval of its multiple myeloma CAR-T therapy Carvykti in the EU the next few weeks, after getting a green light from the EMA’s human medicines committee. The CHMP recommended conditional approval for Carvykti (ciltacabtagene autoleucel or cilta-cel) as a treatment for adults with relapsed and refractory multiple myeloma who have received at least three prior therapies and whose cancer is worsening.

Labelling 98

Labelling Immunization FDA 98

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.